Sign in

    Matthew J. Harrigan

    Research Analyst at Wunderlich Securities, Inc.

    Matthew J. Harrigan is a Managing Director and Senior Equity Research Analyst specializing in Communications Services and Media sectors, with a strong track record of award-winning stock selection and institutional recognition. He has covered major companies and emerging players including Regencell Bioscience, demonstrating insight across a broad range of market capitalizations and consistently engaging with industry leaders like Liberty Media and Qualcomm. Harrigan began his Wall Street career over 25 years ago, previously holding analyst roles at JP Morgan, Bear Stearns, Janco Partners, Buckingham Research Group, Ferris Baker Watts, and WM Smith Securities before his near decade-long tenure at Wunderlich Securities from 2008 to 2017. He holds FINRA registration, maintains active securities licenses, and has earned Institutional Investor rankings and Wall Street Journal ‘Best on the Street’ honors while graduating with distinction from both Wharton and Brown.

    Matthew J. Harrigan's questions to Regencell Bioscience Holdings (RGC) leadership

    Matthew J. Harrigan's questions to Regencell Bioscience Holdings (RGC) leadership • Q2 2016

    Question

    Matthew J. Harrigan from Wunderlich Securities, Inc. inquired if declining mall traffic was creating a performance gap between mall-based and standalone theatres. He also asked for commentary on the upcoming film slate, particularly any potential 'sleeper' hits.

    Answer

    Chairman & CEO Amy E. Miles stated that the company is not seeing any performance divergence between its mall and non-mall locations, as the theatre itself remains the primary draw. She did note a future trend toward building in lifestyle centers. Executive VP, CFO & Treasurer David H. Ownby expressed general optimism for the upcoming film slate but refrained from providing specific box office guidance or highlighting individual films.

    Ask Fintool Equity Research AI